Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Biotechnology

Healthcare
$4.26 +2.67%

+$0.19 today

Market cap
$71.70M
Beta
1.52
P/E (TTM)
0.0
EPS (TTM)
$407.81
52W Low $6.42High $31.50

Volume 0.06M

Average 0.44M

Returns on capital

Enlivex Therapeutics Ltd. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

63.9%

avg -71.5%

ROIC

-0.5%

avg -73.4%

ROA

53.1%

avg -59.3%

Analysis

ROE is currently the strongest return metric at 63.9% versus its period average of -71.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Shai Novik

Executive ChairmanUSD 528K60——

Oren Hershkovitz

Chief Executive OfficerUSD 273.6K49172.85K1.03%

Dror Mevorach

Founder and Scientific AdvisorUSD 180K70——

Shachar Shlosberger

Chief Financial OfficerUSD 126K49139.31K0.83%

Veronique Amor-Baroukh

Senior Director of Operations————

Einat Galamidi

Chief Medical Officer—52156.30K0.93%

Sigal Arad

Director of Human Resources————

Compensation is shown in the reported currency; data updated Jul 9, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 18, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A0 analysts
Net IncomeN/AN/AN/A
N/A0 analysts
EBITN/AN/AN/A
N/A0 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does Enlivex Therapeutics Ltd. compete with?

Open similar companies to compare how their management teams allocate capital.

Competitors

Peer companies in the same sector

Health

Questions

Management questions

Common questions about ENLV's management, answered from reported figures.

Who manages ENLV?

Enlivex Therapeutics Ltd. (ENLV) lists 7 active executives. The top listed executive is Veronique Amor-Baroukh, Senior Director of Operations.

Are ENLV insiders buying or selling?

Recent insider activity shows net selling of $126,764.20.